The Moodivate app relies on behavioral action therapy, encouraging patients to engage in activities that they enjoy or find ...

In this video, the focus is on the challenge of managing depression while maintaining household responsibilities, ...

🎥 The top 5️⃣ goals from the MLS weekend The Major League Soccer All-Star game is creeping up, but the general player pool still put on a show this weekend when it comes to goals. Here are the top ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.

Compass Pathways says a single dose of its synthetic psilocybin significantly reduced depression symptoms in patients who haven’t responded to standard treatments, marking a key milestone in what ...

(Bloomberg) -- Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.Most Read from BloombergBezos Wedding Draws ...

Compass Pathways said Monday it achieved its primary endpoint in an early readout from the largest-ever study of psilocybin for treatment-resistant depression.

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025.

Gao, W., Yan, X., Chen, Y., Yang, J., & Yuan, J. (2024). Situation Covariation and Goal Adaptiveness the Promoting Effect of Cognitive Flexibility on Emotion ...

Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.

(Reuters) -Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study, sending shares of the company down 82% in premarket ...